A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities

NCT03639987 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
52
Enrollment
INDUSTRY
Sponsor class

Stopped Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and NCT02484547) and not based on safety concerns.

Conditions

Interventions

Sponsor

Biogen